{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"79.6","upperLimit":"99.9","value":"96.0"},{"comment":"NA: 95% CI could not be calculated as there was only 1 participant who had low baseline tumor burden","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"100.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Baseline bone marrow tumor burden: Low (<50%)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"62.4","upperLimit":"86.5","value":"75.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Baseline bone marrow tumor burden: High (>=50%)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"Percentage of participants who achieved BOR of CR or CRi by flow cytometry as a function of baseline bone marrow tumor burden.","dispersionType":"95% Confidence Interval","groups":[{"description":"Pediatric patients with relapsed or refractory B-cell ALL who were treated with single dose of tisagenlecleucel (CTL019).","id":"OG000","title":"Main Cohort: Single Dose of CTL019"},{"description":"Pediatric B-ALL patients who are very high risk at first relapse.","id":"OG001","title":"Cohort 1: Single Dose of CTL019"}],"paramType":"NUMBER","populationDescription":"FAS: The Full analysis set comprised all patients who received infusion of tisagenlecleucel with a baseline tumor burden assessment.","reportingStatus":"POSTED","timeFrame":"3 months","title":"Response as a Function of Baseline Tumor Burden (Tumor Load) in Main Cohort Only","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}